FTRE — Fortrea Holdings Inc.
Healthcare · ETF XLV · as of 2026-09-21
Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
Fortrea Holdings Inc.
NMS
Healthcare · Diagnostics & Research
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
Price & today
$20.02
ATR(14) 1.00 (5.02%)
| Stock today | +0.45% |
| Sector ETF today | +0.37% |
| Residual (stock-specific) | +0.08% |
Sector correlation
| 20-day correlation with XLV | 0.28 |
| 60-day correlation with XLV | 0.24 |
| Status | normal |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $19.10 |
| 20 EMA | $18.69 |
| 50 EMA | $18.11 |
| EMA stack | BULLISH |
| RSI(14) | 61.9 |
| 52-week high distance | +7.23% |
| 52-week low distance | +404.28% |
Signals
| Market F&G | 45.1 |
| Bull% | 12.9% |
| OVTLYR status | — |
| Sector rank | — |
| Next earnings | 2026-11-03 (BMO, 42d) |
MarketSmith metrics - our compute
RS Rating
92.8
ADR%
5.0
RMV (tight)
19.0
Ext (ATR>20EMA)
1.3
Rel Vol
72.0%
U/D 50d
1.15
U/D 25d
1.59
Accum/Dist 25d
6 / 3
EPS YoY
+21.0%
LoD dist
35.0
Off 52w High
6.4%
Above 52w Low
141.1%
1W / 1M
+15.0 / +10.1
Avg $Vol 50d
27.5M
Mkt Cap (B)
1.9
Trend 8/8
no
Sector XLV
+0.8% 1W
Base len (VCP)
24wk (6/23)
Coil (base shape)
85TVPX
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
P/E (TTM)
-
Fwd P/E
21.3
PEG
0.3
Price/Book
2.0
Profit margin
-36.2%
ROE
-102.4%
Debt/Equity
198.3
Rev growth
-5.2%
Analyst target
$13 (-37%)
Analyst rating
BUY
Institutional %
102.3%
Insider %
0.7%
Float %
98.2%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.
Company data - context read, not entry inputs
Industry rank
6 / 146
Industry
Diagnostics & Research
Float
92.9M
Float turnover 20d
1.5%
Avg $Vol 20d / 50d
26.1M / 27.5M
Days to cover
9.5
Short % float
13.2%
Institutional %
102.3%
Weinstein stage
2
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Nov-24 | 0.23 | -4% | 674.9 | -5% |
| Mar-25 | 0.18 | -5% | 697.0 | -2% |
| May-25 | 0.02 | - | 651.3 | -2% |
| Aug-25 | 0.19 | - | 710.3 | +7% |
| Nov-25 | 0.12 | -48% | 701.3 | +4% |
| Feb-26 | 0.09 | -50% | 660.5 | -5% |
| May-26 | 0.16 | - | 636.5 | -2% |
| Jul-26 | 0.23 | +21% | 678.2 | -5% |
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 03 + Fortrea übernimmt Einheit für klinische Pharmakologie und bioanalytische Laboraktivitäten von Worldwide Clinical Trials GlobeNewswire Inc.
- Sep 03 + Fortrea acquiert l’unité de pharmacologie clinique et les activités de laboratoire bioanalytique de Worldwide Clinical Trials GlobeNewswire Inc.
- Sep 03 + Fortrea תרכוש את היחידה לפרמקולוגיה קלינית ואת פעילות המעבדה הביו-אנליטית של Worldwide Clinical Trials GlobeNewswire Inc.
- Sep 03 + Fortrea, Worldwide Clinical Trials의 임상약리 유닛·생물분석 연구소 사업 인수 GlobeNewswire Inc.
- Sep 03 + Fortrea Akan Mengambil Alih Unit Farmakologi Klinikal dan Operasi Makmal Bioanalisis daripada Worldwide Clinical Trials GlobeNewswire Inc.
- Sep 03 + Fortrea 将收购 Worldwide Clinical Trials 的临床药理部门和生物分析实验室业务 GlobeNewswire Inc.
- Sep 03 + Fortrea 將收購 Worldwide Clinical Trials 的臨床藥理學部門及生物分析實驗室業務 GlobeNewswire Inc.
- Sep 03 + フォートリア、ワールドワイド・クリニカル・トライアルズから臨床薬理部門およびバイオアナリシスラボ事業を買収 GlobeNewswire Inc.